Robert M et al. - Decreased CA19-9 in patients with metastatic pancreatic cancer treated with FOLFIRINOX versus gemcitabine was evaluated.It was shown that a> 20% decreasein CA19-9 is a prognostic factor for OS and PFS.

Methods

• 342 patients were treated.
• CA19-9 was measured at 8 weeks in 160 of 282 patients with abnormal CA19-9 values at baseline (gemcitabine arm, n = 75; FOLFIRINOX arm, n = 85).
• In the present study, decreased CA19-9 at the 20% and 90% thresholds were analyzed.
• PFS and OS were estimated.

Results

• In the FOLFIRINOX arm, patients with decreased CA19-9 had improved median OS, PFS, and objective response rate.
• Tge median OS and PFS were significantly improved in patients with decreased CA19-9.